DATE – Page 12 – Talk Bio

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

7 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.

GSK’s Vaccine Sales Plummet in Q3, Highlighting Reduced Demand and Market Challenges

8 months ago talkbio0Tagged Arexvy, Demand (clinical), Reduced, Shingrix, SmithKline Beecham, third quarter, Vaccines

GSK, vaccine sales, third quarter, reduced demand, Arexvy, Shingrix, influenza vaccine

Revolution Medicines Advances in Pancreatic Cancer Treatment with RMC-6236 and RMC-9805

8 months ago talkbio0Tagged cellular targeting, Clinical Trials, inhibitors, Pancreatic carcinoma, ras Oncogene, Revolution Medicines, RMC-6236, RMC-9805

Revolution Medicines, RMC-6236, RMC-9805, pancreatic cancer, RAS inhibitors, targeted therapies, clinical trials

Fierce Pharma AsiaAstellas’ first-in-class FDA nod; Otsuka’s IgAN win; Samsung Bio’s $1.2B contract

8 months ago talkbio0Tagged Contract agreement, first, IGA Glomerulonephritis, Samsung, Sibeprenlimab, United States Food and Drug Administration

United States Food and Drug Administration, IGA Glomerulonephritis, Sibeprenlimab, Contract agreement, Samsung, first

CDC Recommends Pneumococcal Vaccination for Adults 50 Years and Older

8 months ago talkbio0Tagged Administration of vaccine product containing only Streptococcus pneumoniae antigen (procedure), Adult, Centers for Disease Control and Prevention (U.S.), older, pneumococcal disease prevention, Recommendation, respiratory season

Pneumococcal vaccination, CDC recommendations, adults 50 and older, pneumococcal disease prevention, winter respiratory season.

Thermo Fisher Forecasts Revenue Growth in 2025 Amid Easing Market Challenges

8 months ago talkbio0Tagged 2025, Analytical Instruments, Growth, headwinds, Laboratory Products, pharmaceutical sector, Thermo Fisher Scientific

Thermo Fisher Scientific, revenue forecast, 2025 growth, easing headwinds, biotech funding, pharmaceutical sector, laboratory products, analytical instruments.